Positive and negative effects of the commensal bacteria on carcinogenesis
Keywords:
microbiota, commensal bacteria, heath, cancer
Abstract
Background: Cancer is a lethal disease that results from a multifactorial process. Progression into carcinogenesis and an abnormal cell proliferation can occur due to the micro and macro environment as well as genetic mutations and modifications. In this review, cancer and the microbiota – mainly bacteria that inhabit the tumour tissue – have been discussed. The positive and negative impacts of the commensal bacteria on tumours being protective or carcinogenic agents, respectively, and their strategies have also been described.
Methods: Related published articles written in English language were searched from Google Scholar, PubMed, Mendeley suggestions, as well as Google search using a combination of the keywords ‘Microbiota, commensal bacteria, cancer, tumor’. Relevant literature published between the years 1979 and 2018 were included in this review.
Results: The complicated nature of cancer as well as the role that might be played by the commensal bacteria in affected tissues have been the focus of the recent studies. The symbiotic relationships between the microbiota and the host have been shown to confer benefits to the last. By contrast, the microbiota has been suggested to upgrade cancer by modifying the balance of host cell proliferation and death, by provoking chronic inflammation, and by eliciting uncontrolled innate and adaptive immunity. In this context, aerobic and anaerobic bacteria have been isolated from various tumor samples.
Conclusions: It can be concluded that commensal microbiota plays an important role in the prevention of diseases including cancer. Inversely, microbiota alterations (dysbiosis) have been found to interrupt that symbiotic correlation between the host and the inhabitant microbiota probably leading to cancer.
Recommendations: The correlation between the commensal microbiome, antibiotics uptake and cancer occurrence need to be investigated exclusively. Moreover, increased attention must be paid to evaluating the effects of these microorganisms on the currently used anticancer agents, and the role that might be played by commensal bacteria on tumor progression or tumor regression.
References
[1] Howlader, N., Noone, A., and Krapcho, M. (2014). SEER Cancer Statistics Review, 1975–2012. Bethesda, Md, USA: National Cancer Institute.
[2] Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell, vol. 140, pp. 883–889.
[3] Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, vol. 144, pp. 646–674.
[4] Jain, R. K. (2001). New approaches for the treatment of the cancer. Advanced Drug Delivery Reviews, vol. 36, pp. 149–168.
[5] Felgner, S., Kocijancic, D., Frahm, M., et al. (2016). Bacteria in Cancer Therapy: Renaissance of an Old Concept. International Journal of Medical Microbiology, vol. 2016, p. 8451728.
[6] Nauts, H. C. and McLaren, J. R. (1990). Coley toxins-the first century. Advances in Experimental Medicine and Biology, vol. 267, pp. 483–500.
[7] Fernandez, M. F., Reina-Perez, I., Astorga, J. M., et al. (2018). Breast cancer and its relationship with the microbiota. International Journal of Environmental Research and Public Health, vol. 15, no. 8, pii: E1747.
[8] Patyar, S., Joshi, R., Byrav, D. S., et al. (2010). Bacteria in cancer therapy: a novel
experimental strategy. Journal of Biomedical Science, vol. 17, no. 1, pp. 21.
[9] Toso, J. F., Gill, V. J., Hwu, P., et al. (2002). Phase I study of the intravenous
administration of attenuated Salmonella typhimurium to patients with metastatic
melanoma. Journal of Clinical Oncology, vol. 20, pp. 142–152.
[10] Nemunaitis, J., Cunningham, C., Senzer, N., et al. (2003). Pilot trial of genetically
modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in
refractory cancer patients. Cancer Gene Therapy, vol. 10, pp. 737–744.
[11] Baban, C. K., Cronin, M., O’Hanlon, D., et al. (2010). Bacteria as vectors for gene
therapy of cancer. Bioengineered Bugs, vol. 1, pp. 385–394.
[12] Liu, S., Xu, X., Zeng, X., et al. (2014). Tumor-targeting bacterial therapy: a potential
treatment for oral cancer. Oncol Letters, vol. 8, pp. 2359–2366.
[13] Lavigne, M. D. and Gorecki, D. C. (2006). Emerging vectors and targeting methods
for nonviral gene therapy. Expert Opinion on Emerging Drugs, vol. 11, pp. 541–557.
[14] Ptak, C. and Petronis, A. (2008). Epigenetics and complex disease: from etiology
to new therapeutics. Annual Review of Pharmacology and Toxicology, vol. 48, pp.
257–276.
[15] Lax, A. J. and Thomas, W. (2002). How bacteria could cause cancer: one step at a
time. Trends in Microbiology, vol. 10, pp. 293–299.
[16] Vogelstein, B., Papadopoulos, N., Velculescu, V. E., et al. (2013). Cancer genome
landscapes. Science, vol. 339, pp. 1546–1558.
[17] Trinchieri, G. (2012). Cancer and inflammation: an old intuition with rapidly evolving
new concepts. Annual Review of Immunology, vol. 30, pp. 677–706.
[18] Backhed, F., Ley, R. E., Sonnenburg, J. L., et al. (2005). Host-bacterial mutualism in
the human intestine. Science, vol. 307, pp. 1915–1920.
[19] Human Microbiome Project Consortium. (2012). Structure, function and diversity of
the healthy human microbiome. Nature, vol. 486, pp. 207–214.
[20] Schlaeppi, K. and Bulgarelli, D. (2015). The plant microbiome at work. Molecular
Plant-Microbe Interactions, vol. 28, pp. 212–217.
[21] Eckburg, P. B., Bik, E. M., Bernstein, C. N., et al. (2005). Diversity of the human
intestinal microbial flora. Science, vol. 308, pp. 1635–1638.
[22] Lax, A. J. (2005). Opinion: bacterial toxins and cancer-a case to answer? Nature
Reviews Microbiology, vol. 3, pp. 343–349.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[23] Brook, I. (1990). Bacteria from solid tumours. Journal of Medical Microbiology, vol.
32, pp. 207–210.
[24] Urbaniak, C., Cummins, J., Brackstone, M., et al. (2014). Microbiota of human breast
tissue. Applied and Environmental Microbiology, vol. 80, pp. 3007–3014.
[25] Hieken, T. J., Chen, J., Hoskin, T. L., et al. (2016). The microbiome of aseptically
collected human breast tissue in benign and malignant disease. Scientific Reports,
vol. 6, p. 30751.
[26] Shaker, D. A. and Lafta, I. J. (2018). Methicillin-resistant Staphylococcus epidermidis
isolated from breast tumors of Iraqi patients. International Journal of Medical
Research and Health Sciences, vol. 7, no. 7, pp. 54–62.
[27] Guidi, R., Guerra, L., Levi, L., et al. (2013). Chronic exposure to the cytolethal
distending toxins of Gram-negative bacteria promotes genomic instability and
altered DNA damage response. Cellular Microbiology, vol. 15, pp. 98–113.
[28] Kamada, N., Kim, Y. G., Sham, H. P., et al. (2012). Regulated virulence controls the
ability of a pathogen to compete with the gut microbiota. Science, vol. 336, pp.
1325–1329.
[29] Kamada, N., Chen, G. Y., Inohara, N., et al. (2013). Control of pathogens and
pathobionts by the gut microbiota. Nature Immunology, vol. 14, pp. 685–690.
[30] Salcedo, R., Worschech, A., Cardone, M., et al. (2010). MyD88-mediated signaling
prevents development of adenocarcinomas of the colon: role of interleukin 18.
Journal of Experimental Medicine, vol. 207, pp. 1625–1636.
[31] Ege, M. J., Mayer, M., Normand, A. C., et al. (2011). Exposure to environmental
microorganisms and childhood asthma. The New England Journal of Medicine, vol.
364, pp. 701–709.
[32] Olszak, T., An, D., Zeissig, S., et al. (2012). Microbial exposure during early life has
persistent effects on natural killer T cell function. Science, vol. 336, pp. 489–493.
[33] Serbina, N. V., Jia, T., Hohl, T. M., et al. (2008). Monocyte-mediated defense against
microbial pathogens. Annual Review of Immunology, vol. 26, pp. 421–452.
[34] Avila, M., Ojcius, D. M., and Yilmaz, O. (2009). The oral microbiota: living with a
permanent guest. DNA and Cell Biology, vol. 28, pp. 405–411.
[35] Hajishengallis, G., Liang, S., Payne, M. A., et al. (2011). Low-abundance biofilm species
orchestrates inflammatory periodontal disease through the commensal microbiota
and complement. Cell Host & Microbe, vol. 10, pp. 497–506.
[36] Hajishengallis, G. and Lamont, R. J. (2014). Breaking bad: manipulation of the host
response by Porphyromonas gingivalis. European Journal of Immunology, vol. 44,
pp. 328–338.
[37] Iwase, T., Uehara, Y., Shinji, H., et al. (2010). Staphylococcus epidermidis Esp inhibits
Staphylococcus aureus biofilm formation and nasal colonization. Nature, vol. 465,
pp. 346–349.
[38] Zipperer, A., Konnerth, M. C., Laux, C., et al. (2016). Human commensals producing
a novel antibiotic impair pathogen colonization. Nature, vol. 535, pp. 511–516.
[39] Xuan, C., Shamonki, J. M., Chung, A., et al. (2014). Microbial dysbiosis is associated
with human breast cancer. PLOS One, vol. 9, e83744.
[40] Belkaid, Y. and Naik, S. (2013) Compartmentalized and systemic control of tissue
immunity by commensals. Nature Immunology, vol. 14, pp. 646–653.
[41] Naik, S., Bouladoux, N., Wilhelm, C., et al. (2012). Compartmentalized control of skin
immunity by resident commensals. Science, vol. 337, pp. 1115–1119.
[42] Chu, H. and Mazmanian, S. K. (2013). Innate immune recognition of the microbiota
promotes host-microbial symbiosis. Nature Immunology, vol. 14, pp. 668–675.
[43] Lai, Y., Di Nardo, A., Nakatsuji, T., et al. (2009). Commensal bacteria regulate Toll-
like receptor 3-dependent inflammation after skin injury. Nature Medicine, vol. 15,
pp. 1377–1382.
[44] Lai, Y., Cogen, A. L., Radek, K. A., et al. (2010). Activation of TLR2 by a small molecule
produced by Staphylococcus epidermidis increases antimicrobial defense against
bacterial skin infections. Journal of Investigative Dermatology, vol. 130, pp. 2211–
2221.
[45] Wanke, I., Steffen, H., Christ, C., et al. (2011). Skin commensals amplify the innate
immune response to pathogens by activation of distinct signaling pathways. Journal
of Investigative Dermatology, vol. 131, pp. 382–390.
[46] Li, D., Lei, H., Li, Z., et al. (2013). A novel lipopeptide from skin commensal activates
TLR2/CD36-p38 MAPK signaling to increase antibacterial defense against bacterial
infection. PLOS ONE, vol. 8, e58288.
[47] Naik, S., Bouladoux, N., Linehan, J. L., et al. (2015). Commensal-dendritic-cell
interaction specifies a unique protective skin immune signature. Nature, vol. 520,
pp. 104–108.
[48] Cogen, A. L., Yamasaki, K., Sanchez, K. M., et al. (2010). Selective antimicrobial action
is provided by phenol-soluble modulins derived from Staphylococcus epidermidis,
a normal resident of the skin. Journal of Investigative Dermatology, vol. 130, pp.
192–200.
[49] Nakatsuji, T., Chen, T. H., Narala, S., et al. (2017). Antimicrobials from human skin
commensal bacteria protect against Staphylococcus aureus and are deficient in
atopic dermatitis. Science Translational Medicine, vol. 9
[50] Cogen, A. L., Yamasaki, K., Muto, J., et al. (2010). Staphylococcus epidermidis
antimicrobial delta-toxin (phenol-soluble modulin-gamma) cooperates with host
antimicrobial peptides to kill group A Streptococcus. PLOS ONE, vol. 5, e8557.
[51] Nakatsuji, T., Chen, T. H., Butcher, A. M., et al. (2018). A commensal strain of
Staphylococcus epidermidis protects against skin neoplasia. Science Advances, vol.
4, no. 3, eaao4502.
[52] Kalina, U., Koyama, N., Hosoda, T., et al. (2002). Enhanced production of IL-18 in
butyrate-treated intestinal epithelium by stimulation of the proximal promoter region.
European Journal of Immunology, vol. 32, pp. 2635–2643.
[53] Singh, N., Gurav, A., Sivaprakasam, S., et al. (2014). Activation of Gpr109a, receptor
for niacin and the commensal metabolite butyrate, suppresses colonic inflammation
and carcinogenesis. Immunity, vol. 40, pp. 128–139.
[54] Huber, S., Gagliani, N., Zenewicz, L. A., et al. (2012). IL-22BP is regulated by the
inflammasome and modulates tumorigenesis in the intestine. Nature, vol. 491, pp.
259–263.
[55] Saleh, M. and Trinchieri, G. (2011). Innate immune mechanisms of colitis and colitis-
associated colorectal cancer. Nature Reviews Immunology, vol. 11, pp. 9–20.
[56] Kirchberger, S., Royston, D. J., Boulard, O., et al. (2013). Innate lymphoid cells sustain
colon cancer through production of interleukin-22 in a mouse model. Journal of
Experimental Medicine, vol. 210, pp. 917–931.
[57] Smith, P. M., Howitt, M. R., Panikov, N., et al. (2013). The microbial metabolites, short-
chain fatty acids, regulate colonic Treg cell homeostasis. Science, vol. 341, pp. 569–
573.
[58] Round, J. L. and Mazmanian, S. K. (2010). Inducible Foxp3+ regulatory T-cell
development by a commensal bacterium of the intestinal microbiota. Proceedings
of the National Academy of Sciences of the United States of America, vol. 107, pp.
12204–12209.
[59] Mazmanian, S. K., Round, J. L., and Kasper, D. L. (2008). A microbial symbiosis factor
prevents intestinal inflammatory disease. Nature, vol. 453, pp. 620–625.
[60] Plottel, C. S. and Blaser, M. J. (2011). Microbiome and malignancy. Cell Host & Microbe,
vol. 10, pp. 324–335.
[61] Velicer, C. M., Lampe, J. W., Heckbert, S. R., et al. (2003). Hypothesis: is antibiotic
use associated with breast cancer? Cancer Causes & Control, vol. 14, pp. 739–747.
[62] Shapiro, T. A., Fahey, J. W., Wade, K. L., et al. (1998). Human metabolism
and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiology, Biomarkers & Prevention, vol. 7, pp.
1091–1100.
[63] Kilkkinen, A., Pietinen, P., Klaukka, T., et al. (2002). Use of oral antimicrobials
decreases serum enterolactone concentration. American Journal of Epidemiology,
vol. 155, pp. 472–477.
[64] Reed, M. J. and Purohit, A. (2001). Aromatase regulation and breast cancer. Clinical
Endocrinology, vol. 54, pp. 563–571.
[65] de Martel, C., Ferlay, J., Franceschi, S., et al. (2012). Global burden of cancers
attributable to infections in 2008: a review and synthetic analysis. The Lancet
Oncology, vol. 13, pp. 607–615.
[66] Dzutsev, A., Goldszmid, R. S., Viaud, S., et al. (2015). The role of the microbiota in
inflammation, carcinogenesis, and cancer therapy. European Journal of Immunology,
vol. 45, pp. 17–31.
[67] Underwood, M. A. (2014). Intestinal dysbiosis: novel mechanisms by which gut
microbes trigger and prevent disease. Preventive Medicine, vol. 65, pp. 133–137.
[68] Frank, D. N., St Amand, A. L., Feldman, R. A., et al. (2007). Molecular-phylogenetic
characterization of microbial community imbalances in human inflammatory bowel
diseases. Proceedings of the National Academy of Sciences of the United States
of America, vol. 104, pp. 13780–13785.
[69] Backhed, F., Ley, R. E., Sonnenburg, J. L., et al. (2005). Host-bacterial mutualism in
the human intestine. Science, vol. 307, pp. 1915–1920.
[70] Rosadi, F., Fiorentini, C., and Fabbri, A. (2016). Bacterial protein toxins in human
cancers. Pathogens and Disease, vol. 74, ftv105.
[71] Allen, I. C., TeKippe, E. M., Woodford, R. M., et al. (2010). The NLRP3 inflammasome
functions as a negative regulator of tumorigenesis during colitis-associated cancer.
Journal of Experimental Medicine, vol. 207, pp. 1045–1056.
[72] Elinav, E., Strowig, T., Kau, A. L., et al. (2011). NLRP6 inflammasome regulates colonic
microbial ecology and risk for colitis. Cell, vol. 145, pp. 745–757.
[73] Kuper, H., Adami, H. O., and Trichopoulos, D. (2000). Infections as a major
preventable cause of human cancer. Journal of Internal Medicine, vol. 248, pp.
171–183.
[74] Correa, P. and Miller, M. J. (1998). Carcinogenesis, apoptosis and cell proliferation.
British Medical Bulletin, vol. 54, pp. 151–162.
[75] Cover, T. L., Glupczynski, Y., Lage, A. P., et al. (1995). Serologic detection of infection
with cagA+ Helicobacter pylori strains. Journal of Clinical Microbiology, vol. 33, pp.
1496–1500. DOI 10.18502/sjms.v14i2.4688 Page 18
[76] Correa, P., Fox, J., Fontham, E., et al. (1990). Helicobacter pylori and gastric carcinoma.
Serum antibody prevalence in populations with contrasting cancer risks. Cancer, vol.
66, pp. 2569–2574.
[77] Montalban, C., Santon, A., Boixeda, D., et al. (2001). Regression of gastric high
grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter
pylori eradication. Gut, vol. 49, pp. 584–587.
[78] Crowe, S. E. (2005). Helicobacter infection, chronic inflammation, and the
development of malignancy. Current Opinion in Gastroenterology, vol. 21, pp. 32–38.
[79] Caygill, C. P., Braddick, M., Hill, M. J., et al. (1995). The association between typhoid
carriage, typhoid infection and subsequent cancer at a number of sites. European
Journal of Cancer Prevention, vol. 4: 187–193.
[80] Dutta, U., Garg, P. K., Kumar, R., et al. (2000). Typhoid carriers among patients with
gallstones are at increased risk for carcinoma of the gallbladder. The American
Journal of Gastroenterology, vol. 95, pp. 784–787.
[81] Shukla, V. K., Singh, H., Pandey, M., et al. (2000). Carcinoma of the gallbladder-is it
a sequel of typhoid? Digestive Diseases and Sciences, vol. 45, pp. 900–903.
[82] Mesnard, B., De Vroey, B., Maunoury, V., et al. (2012). Immunoproliferative small
intestinal disease associated with Campylobacter jejuni. Digestive and Liver Disease,
vol. 44, pp. 799–800.
[83] Zarkin, B. A., Lillemoe, K. D., Cameron, J. L., et al. (1990). The triad of Streptococcus
bovis bacteremia, colonic pathology, and liver disease. Annals of Surgery, vol. 211,
pp. 786–791.
[84] Ellmerich, S., Scholler, M., Duranton, B., et al. (2000). Promotion of intestinal
carcinogenesis by Streptococcus bovis. Carcinogenesis, vol. 21, pp. 753–756.
[85] Gold, J. S., Bayar, S., and Salem, R. R. (2004). Association of Streptococcus bovis
bacteremia with colonic neoplasia and extracolonic malignancy. The Archives of
Surgery, vol. 139, pp. 760–765.
[86] Luperchio, S. A., Newman, J. V., Dangler, C. A., et al. (2000). Citrobacter rodentium,
the causative agent of transmissible murine colonic hyperplasia, exhibits clonality:
synonymy of C. rodentium and mouse-pathogenic Escherichia coli. Journal of
Clinical Microbiology, vol. 38, pp. 4343–4350.
[87] Kostic, A. D., Chun, E., Robertson, L., et al. (2013). Fusobacterium nucleatum poten-
tiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
Cell Host & Microbe, vol. 14, pp. 207–215.
[88] McCoy, A. N., Araujo-Perez, F., Azcarate-Peril, A., et al. (2013). Fusobacterium is
associated with colorectal adenomas. PLOS ONE, vol. 8, e53653.
[89] Koyi, H., Branden, E., Gnarpe, J., et al. (2001). An association between chronic
infection with Chlamydia pneumoniae and lung cancer. a prospective 2-year study.
APMIS, vol. 109, pp. 572–580.
[90] Anttila, T., Koskela, P., Leinonen, M., et al. (2003). Chlamydia pneumoniae infection
and the risk of female early-onset lung cancer. International Journal of Cancer, vol.
107, pp. 681–682.
[91] Littman, A. J., White, E., Jackson, L. A., et al. (2004). Chlamydia pneumoniae infection
and risk of lung cancer. Cancer Epidemiology, Biomarkers & Prevention, vol. 13, pp.
1624–1630.
[92] Gupta, P. K., Tripathi, D., Kulkarni, S., et al. (2016). Mycobacterium tuberculosis
H37Rv infected THP-1 cells induce epithelial mesenchymal transition (EMT) in lung
adenocarcinoma epithelial cell line (A549). Cellular Immunology, vol. 300, pp. 33–40.
[93] Ferreri, A. J., Guidoboni, M., Ponzoni, M., et al. (2004). Evidence for an association
between Chlamydia psittaci and ocular adnexal lymphomas. Journal of the National
Cancer Institute, vol. 96, pp. 586–594.
[94] De Spiegeleer, B., Verbeke, F., D’Hondt, M., et al. (2015). The quorum sensing
peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer
cells in vitro. PLOS ONE, vol. 10, e0119471.
[95] Jacob, J. A. (2016). Study links periodontal disease bacteria to pancreatic cancer
risk. JAMA, vol. 315, pp. 2653–2654.
[96] Iida, N., Dzutsev, A., Stewart, C. A., et al. (2013). Commensal bacteria control cancer
response to therapy by modulating the tumor microenvironment. Science, vol. 342,
pp. 967–970.
[97] Mukherji, A., Kobiita, A., Ye, T., et al. (2013). Homeostasis in intestinal epithelium is
orchestrated by the circadian clock and microbiota cues transduced by TLRs. Cell,
vol. 153, pp. 812–827.
[98] Khosravi, A., Yanez, A., Price, J. G., et al. (2014). Gut microbiota promote
hematopoiesis to control bacterial infection. Cell Host & Microbe, vol. 15, pp. 374–381.
[99] Rubinstein, M. R., Wang, X., Liu, W., et al. (2013). Fusobacterium nucleatum promotes
colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its
FadA adhesin. Cell Host & Microbe, vol. 14, pp. 195–206.
[100] Sears, C. L. and Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. Cell
Host & Microbe, vol. 15, pp. 317–328.
[101] Mackowiak, P. A. (1987). Microbial oncogenesis. The American Journal of Medicine,
vol. 82, pp. 79–97.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[102] Hussain, S. P., Hofseth, L. J., and Harris, C. C. (2003). Radical causes of cancer.
Nature Reviews Cancer, vol. 3, pp. 276–285.
[103] Schetter, A. J., Heegaard, N. H., and Harris, C. C. (2010). Inflammation and cancer:
interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis,
vol. 31, pp. 37–49.
[104] Poutahidis, T., Cappelle, K., Levkovich, T., et al. (2013). Pathogenic intestinal bacteria
enhance prostate cancer development via systemic activation of immune cells in
mice. PLOS ONE, vol. 8, e73933.
[105] Yamamoto, M. L., Maier, I., Dang, A. T., et al. (2013). Intestinal bacteria modify
lymphoma incidence and latency by affecting systemic inflammatory state, oxidative
stress, and leukocyte genotoxicity. Cancer Research, vol. 73, pp. 4222–4232.
[106] Mulvey, M. A., Schilling, J. D., and Hultgren, S. J. (2001). Establishment of a persistent
Escherichia coli reservoir during the acute phase of a bladder infection. Infection and
Immunity, vol. 69, pp. 4572–4579.
[107] Shurin, S. B., Socransky, S. S., Sweeney, E., et al. (1979). A neutrophil disorder induced
by capnocytophaga, a dental microorganism. The New England Journal of Medicine,
vol. 301, pp. 849–854.
[108] Kilian, M. (1981). Degradation of immunoglobulins A2, A2, and G by suspected
principal periodontal pathogens. Infection and Immunity, vol. 34, pp. 757–765.
[109] Nougayrede, J. P., Taieb, F., De Rycke, J., et al. (2005). Cyclomodulins: bacterial
effectors that modulate the eukaryotic cell cycle. Trends in Microbiology, vol. 13, pp.
103–110.
[110] Lax, A. J. (2005). Opinion: bacterial toxins and cancer–a case to answer? Nature
Reviews Microbiology, vol. 3, pp. 343–349.
[111] Urbaniak, C., Gloor, G. B., Brackstone, M., et al. (2016). The microbiota of breast tissue
and its association with breast cancer. Applied and Environmental Microbiology, vol.
82, pp. 5039–5048.
[112] Koller, V. J., Marian, B., Stidl, R., et al. (2008). Impact of lactic acid bacteria on oxidative
DNA damage in human derived colon cells. Food and Chemical Toxicology, vol. 46,
pp. 1221–1229.
[113] Putze, J., Hennequin, C., Nougayrede, J. P., et al. (2009). Genetic structure
and distribution of the colibactin genomic island among members of the family
Enterobacteriaceae. Infection and Immunity, 77, pp. 4696–4703.
[114] Buc, E., Dubois, D., Sauvanet, P., et al. (2013). High prevalence of mucosa-associated
E. coli producing cyclomodulin and genotoxin in colon cancer. PLOS ONE, vol. 8,
e56964.
[115] Oswald, E., Sugai, M., Labigne, A., et al. (1994). Cytotoxic necrotizing factor type 2
produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho
involved in assembly of actin stress fibers. Proceedings of the National Academy of
Sciences of the United States of America, vol. 91, pp. 3814–3818.
[116] Smith, J. L. and Bayles, D. O. (2006). The contribution of cytolethal distending toxin
to bacterial pathogenesis. Critical Reviews in Microbiology, vol. 32, pp. 227–248.
[117] Marches, O., Ledger, T. N., Boury, M., et al. (2003). Enteropathogenic and
enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks
cell cycle G2/M transition. Molecular Microbiology, vol. 50, pp. 1553–1567.
[118] Thelestam, M. and Frisan, T. (2006). Cytolethal distending toxins, in Alouf J, Popoff M
(ed.) The comprehensive sourcebook of bacterial protein toxins, pp. 448–467. San
Diego, USA: Elsevier, Academic Press.
[119] Haghjoo, E. and Galan, J. E. (2004). Salmonella typhi encodes a functional cytolethal
distending toxin that is delivered into host cells by a bacterial-internalization pathway.
Proceedings of the National Academy of Sciences of the United States of America,
vol. 101, pp. 4614–4619.
[120] Winter, J. A., Letley, D. P., Cook, K. W., et al. (2014). A role for the vacuolating cytotoxin,
VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach.
The Journal of Infectious Diseases, vol. 210, pp. 954–963.
[121] Neal, J. T., Peterson, T. S., Kent, M. L., et al. (2013). Pylori virulence factor CagA
increases intestinal cell proliferation by Wnt pathway activation in a transgenic
zebrafish model. Disease Models & Mechanisms, vol. 6, pp. 802–810.
[122] Lu, R., Wu, S., Zhang, Y. G., et al. (2014). Enteric bacterial protein AvrA promotes
colonic tumorigenesis and activates colonic beta-catenin signaling pathway.
Oncogenesis, vol. 3, e105.
[123] Rhee, K. J., Wu, S., Wu, X., et al. (2009). Induction of persistent colitis by a
human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice.
Infection and Immunity, vol. 77, pp. 1708–1718.
[124] Dabek, M., McCrae, S. I., Stevens, V. J., et al. (2008). Distribution of beta-glucosidase
and beta-glucuronidase activity and of beta-glucuronidase gene gus in human
colonic bacteria. FEMS Microbiology Ecology, vol., 66, pp. 487–495.
[125] DeLuca, J. A., Allred, K. F., Menon, R., et al. (2018). Bisphenol-A alters microbiota
metabolites derived from aromatic amino acids and worsens disease activity during
colitis. Experimental Biology and Medicine, vol. 243, pp. 864–875.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[126] Wynendaele, E., Verbeke, F., D’Hondt, M., et al. (2015). Crosstalk between the
microbiome and cancer cells by quorum sensing peptides. Peptides, vol. 64, pp.
40–48.
[2] Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell, vol. 140, pp. 883–889.
[3] Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, vol. 144, pp. 646–674.
[4] Jain, R. K. (2001). New approaches for the treatment of the cancer. Advanced Drug Delivery Reviews, vol. 36, pp. 149–168.
[5] Felgner, S., Kocijancic, D., Frahm, M., et al. (2016). Bacteria in Cancer Therapy: Renaissance of an Old Concept. International Journal of Medical Microbiology, vol. 2016, p. 8451728.
[6] Nauts, H. C. and McLaren, J. R. (1990). Coley toxins-the first century. Advances in Experimental Medicine and Biology, vol. 267, pp. 483–500.
[7] Fernandez, M. F., Reina-Perez, I., Astorga, J. M., et al. (2018). Breast cancer and its relationship with the microbiota. International Journal of Environmental Research and Public Health, vol. 15, no. 8, pii: E1747.
[8] Patyar, S., Joshi, R., Byrav, D. S., et al. (2010). Bacteria in cancer therapy: a novel
experimental strategy. Journal of Biomedical Science, vol. 17, no. 1, pp. 21.
[9] Toso, J. F., Gill, V. J., Hwu, P., et al. (2002). Phase I study of the intravenous
administration of attenuated Salmonella typhimurium to patients with metastatic
melanoma. Journal of Clinical Oncology, vol. 20, pp. 142–152.
[10] Nemunaitis, J., Cunningham, C., Senzer, N., et al. (2003). Pilot trial of genetically
modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in
refractory cancer patients. Cancer Gene Therapy, vol. 10, pp. 737–744.
[11] Baban, C. K., Cronin, M., O’Hanlon, D., et al. (2010). Bacteria as vectors for gene
therapy of cancer. Bioengineered Bugs, vol. 1, pp. 385–394.
[12] Liu, S., Xu, X., Zeng, X., et al. (2014). Tumor-targeting bacterial therapy: a potential
treatment for oral cancer. Oncol Letters, vol. 8, pp. 2359–2366.
[13] Lavigne, M. D. and Gorecki, D. C. (2006). Emerging vectors and targeting methods
for nonviral gene therapy. Expert Opinion on Emerging Drugs, vol. 11, pp. 541–557.
[14] Ptak, C. and Petronis, A. (2008). Epigenetics and complex disease: from etiology
to new therapeutics. Annual Review of Pharmacology and Toxicology, vol. 48, pp.
257–276.
[15] Lax, A. J. and Thomas, W. (2002). How bacteria could cause cancer: one step at a
time. Trends in Microbiology, vol. 10, pp. 293–299.
[16] Vogelstein, B., Papadopoulos, N., Velculescu, V. E., et al. (2013). Cancer genome
landscapes. Science, vol. 339, pp. 1546–1558.
[17] Trinchieri, G. (2012). Cancer and inflammation: an old intuition with rapidly evolving
new concepts. Annual Review of Immunology, vol. 30, pp. 677–706.
[18] Backhed, F., Ley, R. E., Sonnenburg, J. L., et al. (2005). Host-bacterial mutualism in
the human intestine. Science, vol. 307, pp. 1915–1920.
[19] Human Microbiome Project Consortium. (2012). Structure, function and diversity of
the healthy human microbiome. Nature, vol. 486, pp. 207–214.
[20] Schlaeppi, K. and Bulgarelli, D. (2015). The plant microbiome at work. Molecular
Plant-Microbe Interactions, vol. 28, pp. 212–217.
[21] Eckburg, P. B., Bik, E. M., Bernstein, C. N., et al. (2005). Diversity of the human
intestinal microbial flora. Science, vol. 308, pp. 1635–1638.
[22] Lax, A. J. (2005). Opinion: bacterial toxins and cancer-a case to answer? Nature
Reviews Microbiology, vol. 3, pp. 343–349.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[23] Brook, I. (1990). Bacteria from solid tumours. Journal of Medical Microbiology, vol.
32, pp. 207–210.
[24] Urbaniak, C., Cummins, J., Brackstone, M., et al. (2014). Microbiota of human breast
tissue. Applied and Environmental Microbiology, vol. 80, pp. 3007–3014.
[25] Hieken, T. J., Chen, J., Hoskin, T. L., et al. (2016). The microbiome of aseptically
collected human breast tissue in benign and malignant disease. Scientific Reports,
vol. 6, p. 30751.
[26] Shaker, D. A. and Lafta, I. J. (2018). Methicillin-resistant Staphylococcus epidermidis
isolated from breast tumors of Iraqi patients. International Journal of Medical
Research and Health Sciences, vol. 7, no. 7, pp. 54–62.
[27] Guidi, R., Guerra, L., Levi, L., et al. (2013). Chronic exposure to the cytolethal
distending toxins of Gram-negative bacteria promotes genomic instability and
altered DNA damage response. Cellular Microbiology, vol. 15, pp. 98–113.
[28] Kamada, N., Kim, Y. G., Sham, H. P., et al. (2012). Regulated virulence controls the
ability of a pathogen to compete with the gut microbiota. Science, vol. 336, pp.
1325–1329.
[29] Kamada, N., Chen, G. Y., Inohara, N., et al. (2013). Control of pathogens and
pathobionts by the gut microbiota. Nature Immunology, vol. 14, pp. 685–690.
[30] Salcedo, R., Worschech, A., Cardone, M., et al. (2010). MyD88-mediated signaling
prevents development of adenocarcinomas of the colon: role of interleukin 18.
Journal of Experimental Medicine, vol. 207, pp. 1625–1636.
[31] Ege, M. J., Mayer, M., Normand, A. C., et al. (2011). Exposure to environmental
microorganisms and childhood asthma. The New England Journal of Medicine, vol.
364, pp. 701–709.
[32] Olszak, T., An, D., Zeissig, S., et al. (2012). Microbial exposure during early life has
persistent effects on natural killer T cell function. Science, vol. 336, pp. 489–493.
[33] Serbina, N. V., Jia, T., Hohl, T. M., et al. (2008). Monocyte-mediated defense against
microbial pathogens. Annual Review of Immunology, vol. 26, pp. 421–452.
[34] Avila, M., Ojcius, D. M., and Yilmaz, O. (2009). The oral microbiota: living with a
permanent guest. DNA and Cell Biology, vol. 28, pp. 405–411.
[35] Hajishengallis, G., Liang, S., Payne, M. A., et al. (2011). Low-abundance biofilm species
orchestrates inflammatory periodontal disease through the commensal microbiota
and complement. Cell Host & Microbe, vol. 10, pp. 497–506.
[36] Hajishengallis, G. and Lamont, R. J. (2014). Breaking bad: manipulation of the host
response by Porphyromonas gingivalis. European Journal of Immunology, vol. 44,
pp. 328–338.
[37] Iwase, T., Uehara, Y., Shinji, H., et al. (2010). Staphylococcus epidermidis Esp inhibits
Staphylococcus aureus biofilm formation and nasal colonization. Nature, vol. 465,
pp. 346–349.
[38] Zipperer, A., Konnerth, M. C., Laux, C., et al. (2016). Human commensals producing
a novel antibiotic impair pathogen colonization. Nature, vol. 535, pp. 511–516.
[39] Xuan, C., Shamonki, J. M., Chung, A., et al. (2014). Microbial dysbiosis is associated
with human breast cancer. PLOS One, vol. 9, e83744.
[40] Belkaid, Y. and Naik, S. (2013) Compartmentalized and systemic control of tissue
immunity by commensals. Nature Immunology, vol. 14, pp. 646–653.
[41] Naik, S., Bouladoux, N., Wilhelm, C., et al. (2012). Compartmentalized control of skin
immunity by resident commensals. Science, vol. 337, pp. 1115–1119.
[42] Chu, H. and Mazmanian, S. K. (2013). Innate immune recognition of the microbiota
promotes host-microbial symbiosis. Nature Immunology, vol. 14, pp. 668–675.
[43] Lai, Y., Di Nardo, A., Nakatsuji, T., et al. (2009). Commensal bacteria regulate Toll-
like receptor 3-dependent inflammation after skin injury. Nature Medicine, vol. 15,
pp. 1377–1382.
[44] Lai, Y., Cogen, A. L., Radek, K. A., et al. (2010). Activation of TLR2 by a small molecule
produced by Staphylococcus epidermidis increases antimicrobial defense against
bacterial skin infections. Journal of Investigative Dermatology, vol. 130, pp. 2211–
2221.
[45] Wanke, I., Steffen, H., Christ, C., et al. (2011). Skin commensals amplify the innate
immune response to pathogens by activation of distinct signaling pathways. Journal
of Investigative Dermatology, vol. 131, pp. 382–390.
[46] Li, D., Lei, H., Li, Z., et al. (2013). A novel lipopeptide from skin commensal activates
TLR2/CD36-p38 MAPK signaling to increase antibacterial defense against bacterial
infection. PLOS ONE, vol. 8, e58288.
[47] Naik, S., Bouladoux, N., Linehan, J. L., et al. (2015). Commensal-dendritic-cell
interaction specifies a unique protective skin immune signature. Nature, vol. 520,
pp. 104–108.
[48] Cogen, A. L., Yamasaki, K., Sanchez, K. M., et al. (2010). Selective antimicrobial action
is provided by phenol-soluble modulins derived from Staphylococcus epidermidis,
a normal resident of the skin. Journal of Investigative Dermatology, vol. 130, pp.
192–200.
[49] Nakatsuji, T., Chen, T. H., Narala, S., et al. (2017). Antimicrobials from human skin
commensal bacteria protect against Staphylococcus aureus and are deficient in
atopic dermatitis. Science Translational Medicine, vol. 9
[50] Cogen, A. L., Yamasaki, K., Muto, J., et al. (2010). Staphylococcus epidermidis
antimicrobial delta-toxin (phenol-soluble modulin-gamma) cooperates with host
antimicrobial peptides to kill group A Streptococcus. PLOS ONE, vol. 5, e8557.
[51] Nakatsuji, T., Chen, T. H., Butcher, A. M., et al. (2018). A commensal strain of
Staphylococcus epidermidis protects against skin neoplasia. Science Advances, vol.
4, no. 3, eaao4502.
[52] Kalina, U., Koyama, N., Hosoda, T., et al. (2002). Enhanced production of IL-18 in
butyrate-treated intestinal epithelium by stimulation of the proximal promoter region.
European Journal of Immunology, vol. 32, pp. 2635–2643.
[53] Singh, N., Gurav, A., Sivaprakasam, S., et al. (2014). Activation of Gpr109a, receptor
for niacin and the commensal metabolite butyrate, suppresses colonic inflammation
and carcinogenesis. Immunity, vol. 40, pp. 128–139.
[54] Huber, S., Gagliani, N., Zenewicz, L. A., et al. (2012). IL-22BP is regulated by the
inflammasome and modulates tumorigenesis in the intestine. Nature, vol. 491, pp.
259–263.
[55] Saleh, M. and Trinchieri, G. (2011). Innate immune mechanisms of colitis and colitis-
associated colorectal cancer. Nature Reviews Immunology, vol. 11, pp. 9–20.
[56] Kirchberger, S., Royston, D. J., Boulard, O., et al. (2013). Innate lymphoid cells sustain
colon cancer through production of interleukin-22 in a mouse model. Journal of
Experimental Medicine, vol. 210, pp. 917–931.
[57] Smith, P. M., Howitt, M. R., Panikov, N., et al. (2013). The microbial metabolites, short-
chain fatty acids, regulate colonic Treg cell homeostasis. Science, vol. 341, pp. 569–
573.
[58] Round, J. L. and Mazmanian, S. K. (2010). Inducible Foxp3+ regulatory T-cell
development by a commensal bacterium of the intestinal microbiota. Proceedings
of the National Academy of Sciences of the United States of America, vol. 107, pp.
12204–12209.
[59] Mazmanian, S. K., Round, J. L., and Kasper, D. L. (2008). A microbial symbiosis factor
prevents intestinal inflammatory disease. Nature, vol. 453, pp. 620–625.
[60] Plottel, C. S. and Blaser, M. J. (2011). Microbiome and malignancy. Cell Host & Microbe,
vol. 10, pp. 324–335.
[61] Velicer, C. M., Lampe, J. W., Heckbert, S. R., et al. (2003). Hypothesis: is antibiotic
use associated with breast cancer? Cancer Causes & Control, vol. 14, pp. 739–747.
[62] Shapiro, T. A., Fahey, J. W., Wade, K. L., et al. (1998). Human metabolism
and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiology, Biomarkers & Prevention, vol. 7, pp.
1091–1100.
[63] Kilkkinen, A., Pietinen, P., Klaukka, T., et al. (2002). Use of oral antimicrobials
decreases serum enterolactone concentration. American Journal of Epidemiology,
vol. 155, pp. 472–477.
[64] Reed, M. J. and Purohit, A. (2001). Aromatase regulation and breast cancer. Clinical
Endocrinology, vol. 54, pp. 563–571.
[65] de Martel, C., Ferlay, J., Franceschi, S., et al. (2012). Global burden of cancers
attributable to infections in 2008: a review and synthetic analysis. The Lancet
Oncology, vol. 13, pp. 607–615.
[66] Dzutsev, A., Goldszmid, R. S., Viaud, S., et al. (2015). The role of the microbiota in
inflammation, carcinogenesis, and cancer therapy. European Journal of Immunology,
vol. 45, pp. 17–31.
[67] Underwood, M. A. (2014). Intestinal dysbiosis: novel mechanisms by which gut
microbes trigger and prevent disease. Preventive Medicine, vol. 65, pp. 133–137.
[68] Frank, D. N., St Amand, A. L., Feldman, R. A., et al. (2007). Molecular-phylogenetic
characterization of microbial community imbalances in human inflammatory bowel
diseases. Proceedings of the National Academy of Sciences of the United States
of America, vol. 104, pp. 13780–13785.
[69] Backhed, F., Ley, R. E., Sonnenburg, J. L., et al. (2005). Host-bacterial mutualism in
the human intestine. Science, vol. 307, pp. 1915–1920.
[70] Rosadi, F., Fiorentini, C., and Fabbri, A. (2016). Bacterial protein toxins in human
cancers. Pathogens and Disease, vol. 74, ftv105.
[71] Allen, I. C., TeKippe, E. M., Woodford, R. M., et al. (2010). The NLRP3 inflammasome
functions as a negative regulator of tumorigenesis during colitis-associated cancer.
Journal of Experimental Medicine, vol. 207, pp. 1045–1056.
[72] Elinav, E., Strowig, T., Kau, A. L., et al. (2011). NLRP6 inflammasome regulates colonic
microbial ecology and risk for colitis. Cell, vol. 145, pp. 745–757.
[73] Kuper, H., Adami, H. O., and Trichopoulos, D. (2000). Infections as a major
preventable cause of human cancer. Journal of Internal Medicine, vol. 248, pp.
171–183.
[74] Correa, P. and Miller, M. J. (1998). Carcinogenesis, apoptosis and cell proliferation.
British Medical Bulletin, vol. 54, pp. 151–162.
[75] Cover, T. L., Glupczynski, Y., Lage, A. P., et al. (1995). Serologic detection of infection
with cagA+ Helicobacter pylori strains. Journal of Clinical Microbiology, vol. 33, pp.
1496–1500. DOI 10.18502/sjms.v14i2.4688 Page 18
[76] Correa, P., Fox, J., Fontham, E., et al. (1990). Helicobacter pylori and gastric carcinoma.
Serum antibody prevalence in populations with contrasting cancer risks. Cancer, vol.
66, pp. 2569–2574.
[77] Montalban, C., Santon, A., Boixeda, D., et al. (2001). Regression of gastric high
grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter
pylori eradication. Gut, vol. 49, pp. 584–587.
[78] Crowe, S. E. (2005). Helicobacter infection, chronic inflammation, and the
development of malignancy. Current Opinion in Gastroenterology, vol. 21, pp. 32–38.
[79] Caygill, C. P., Braddick, M., Hill, M. J., et al. (1995). The association between typhoid
carriage, typhoid infection and subsequent cancer at a number of sites. European
Journal of Cancer Prevention, vol. 4: 187–193.
[80] Dutta, U., Garg, P. K., Kumar, R., et al. (2000). Typhoid carriers among patients with
gallstones are at increased risk for carcinoma of the gallbladder. The American
Journal of Gastroenterology, vol. 95, pp. 784–787.
[81] Shukla, V. K., Singh, H., Pandey, M., et al. (2000). Carcinoma of the gallbladder-is it
a sequel of typhoid? Digestive Diseases and Sciences, vol. 45, pp. 900–903.
[82] Mesnard, B., De Vroey, B., Maunoury, V., et al. (2012). Immunoproliferative small
intestinal disease associated with Campylobacter jejuni. Digestive and Liver Disease,
vol. 44, pp. 799–800.
[83] Zarkin, B. A., Lillemoe, K. D., Cameron, J. L., et al. (1990). The triad of Streptococcus
bovis bacteremia, colonic pathology, and liver disease. Annals of Surgery, vol. 211,
pp. 786–791.
[84] Ellmerich, S., Scholler, M., Duranton, B., et al. (2000). Promotion of intestinal
carcinogenesis by Streptococcus bovis. Carcinogenesis, vol. 21, pp. 753–756.
[85] Gold, J. S., Bayar, S., and Salem, R. R. (2004). Association of Streptococcus bovis
bacteremia with colonic neoplasia and extracolonic malignancy. The Archives of
Surgery, vol. 139, pp. 760–765.
[86] Luperchio, S. A., Newman, J. V., Dangler, C. A., et al. (2000). Citrobacter rodentium,
the causative agent of transmissible murine colonic hyperplasia, exhibits clonality:
synonymy of C. rodentium and mouse-pathogenic Escherichia coli. Journal of
Clinical Microbiology, vol. 38, pp. 4343–4350.
[87] Kostic, A. D., Chun, E., Robertson, L., et al. (2013). Fusobacterium nucleatum poten-
tiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
Cell Host & Microbe, vol. 14, pp. 207–215.
[88] McCoy, A. N., Araujo-Perez, F., Azcarate-Peril, A., et al. (2013). Fusobacterium is
associated with colorectal adenomas. PLOS ONE, vol. 8, e53653.
[89] Koyi, H., Branden, E., Gnarpe, J., et al. (2001). An association between chronic
infection with Chlamydia pneumoniae and lung cancer. a prospective 2-year study.
APMIS, vol. 109, pp. 572–580.
[90] Anttila, T., Koskela, P., Leinonen, M., et al. (2003). Chlamydia pneumoniae infection
and the risk of female early-onset lung cancer. International Journal of Cancer, vol.
107, pp. 681–682.
[91] Littman, A. J., White, E., Jackson, L. A., et al. (2004). Chlamydia pneumoniae infection
and risk of lung cancer. Cancer Epidemiology, Biomarkers & Prevention, vol. 13, pp.
1624–1630.
[92] Gupta, P. K., Tripathi, D., Kulkarni, S., et al. (2016). Mycobacterium tuberculosis
H37Rv infected THP-1 cells induce epithelial mesenchymal transition (EMT) in lung
adenocarcinoma epithelial cell line (A549). Cellular Immunology, vol. 300, pp. 33–40.
[93] Ferreri, A. J., Guidoboni, M., Ponzoni, M., et al. (2004). Evidence for an association
between Chlamydia psittaci and ocular adnexal lymphomas. Journal of the National
Cancer Institute, vol. 96, pp. 586–594.
[94] De Spiegeleer, B., Verbeke, F., D’Hondt, M., et al. (2015). The quorum sensing
peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer
cells in vitro. PLOS ONE, vol. 10, e0119471.
[95] Jacob, J. A. (2016). Study links periodontal disease bacteria to pancreatic cancer
risk. JAMA, vol. 315, pp. 2653–2654.
[96] Iida, N., Dzutsev, A., Stewart, C. A., et al. (2013). Commensal bacteria control cancer
response to therapy by modulating the tumor microenvironment. Science, vol. 342,
pp. 967–970.
[97] Mukherji, A., Kobiita, A., Ye, T., et al. (2013). Homeostasis in intestinal epithelium is
orchestrated by the circadian clock and microbiota cues transduced by TLRs. Cell,
vol. 153, pp. 812–827.
[98] Khosravi, A., Yanez, A., Price, J. G., et al. (2014). Gut microbiota promote
hematopoiesis to control bacterial infection. Cell Host & Microbe, vol. 15, pp. 374–381.
[99] Rubinstein, M. R., Wang, X., Liu, W., et al. (2013). Fusobacterium nucleatum promotes
colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its
FadA adhesin. Cell Host & Microbe, vol. 14, pp. 195–206.
[100] Sears, C. L. and Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. Cell
Host & Microbe, vol. 15, pp. 317–328.
[101] Mackowiak, P. A. (1987). Microbial oncogenesis. The American Journal of Medicine,
vol. 82, pp. 79–97.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[102] Hussain, S. P., Hofseth, L. J., and Harris, C. C. (2003). Radical causes of cancer.
Nature Reviews Cancer, vol. 3, pp. 276–285.
[103] Schetter, A. J., Heegaard, N. H., and Harris, C. C. (2010). Inflammation and cancer:
interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis,
vol. 31, pp. 37–49.
[104] Poutahidis, T., Cappelle, K., Levkovich, T., et al. (2013). Pathogenic intestinal bacteria
enhance prostate cancer development via systemic activation of immune cells in
mice. PLOS ONE, vol. 8, e73933.
[105] Yamamoto, M. L., Maier, I., Dang, A. T., et al. (2013). Intestinal bacteria modify
lymphoma incidence and latency by affecting systemic inflammatory state, oxidative
stress, and leukocyte genotoxicity. Cancer Research, vol. 73, pp. 4222–4232.
[106] Mulvey, M. A., Schilling, J. D., and Hultgren, S. J. (2001). Establishment of a persistent
Escherichia coli reservoir during the acute phase of a bladder infection. Infection and
Immunity, vol. 69, pp. 4572–4579.
[107] Shurin, S. B., Socransky, S. S., Sweeney, E., et al. (1979). A neutrophil disorder induced
by capnocytophaga, a dental microorganism. The New England Journal of Medicine,
vol. 301, pp. 849–854.
[108] Kilian, M. (1981). Degradation of immunoglobulins A2, A2, and G by suspected
principal periodontal pathogens. Infection and Immunity, vol. 34, pp. 757–765.
[109] Nougayrede, J. P., Taieb, F., De Rycke, J., et al. (2005). Cyclomodulins: bacterial
effectors that modulate the eukaryotic cell cycle. Trends in Microbiology, vol. 13, pp.
103–110.
[110] Lax, A. J. (2005). Opinion: bacterial toxins and cancer–a case to answer? Nature
Reviews Microbiology, vol. 3, pp. 343–349.
[111] Urbaniak, C., Gloor, G. B., Brackstone, M., et al. (2016). The microbiota of breast tissue
and its association with breast cancer. Applied and Environmental Microbiology, vol.
82, pp. 5039–5048.
[112] Koller, V. J., Marian, B., Stidl, R., et al. (2008). Impact of lactic acid bacteria on oxidative
DNA damage in human derived colon cells. Food and Chemical Toxicology, vol. 46,
pp. 1221–1229.
[113] Putze, J., Hennequin, C., Nougayrede, J. P., et al. (2009). Genetic structure
and distribution of the colibactin genomic island among members of the family
Enterobacteriaceae. Infection and Immunity, 77, pp. 4696–4703.
[114] Buc, E., Dubois, D., Sauvanet, P., et al. (2013). High prevalence of mucosa-associated
E. coli producing cyclomodulin and genotoxin in colon cancer. PLOS ONE, vol. 8,
e56964.
[115] Oswald, E., Sugai, M., Labigne, A., et al. (1994). Cytotoxic necrotizing factor type 2
produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho
involved in assembly of actin stress fibers. Proceedings of the National Academy of
Sciences of the United States of America, vol. 91, pp. 3814–3818.
[116] Smith, J. L. and Bayles, D. O. (2006). The contribution of cytolethal distending toxin
to bacterial pathogenesis. Critical Reviews in Microbiology, vol. 32, pp. 227–248.
[117] Marches, O., Ledger, T. N., Boury, M., et al. (2003). Enteropathogenic and
enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks
cell cycle G2/M transition. Molecular Microbiology, vol. 50, pp. 1553–1567.
[118] Thelestam, M. and Frisan, T. (2006). Cytolethal distending toxins, in Alouf J, Popoff M
(ed.) The comprehensive sourcebook of bacterial protein toxins, pp. 448–467. San
Diego, USA: Elsevier, Academic Press.
[119] Haghjoo, E. and Galan, J. E. (2004). Salmonella typhi encodes a functional cytolethal
distending toxin that is delivered into host cells by a bacterial-internalization pathway.
Proceedings of the National Academy of Sciences of the United States of America,
vol. 101, pp. 4614–4619.
[120] Winter, J. A., Letley, D. P., Cook, K. W., et al. (2014). A role for the vacuolating cytotoxin,
VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach.
The Journal of Infectious Diseases, vol. 210, pp. 954–963.
[121] Neal, J. T., Peterson, T. S., Kent, M. L., et al. (2013). Pylori virulence factor CagA
increases intestinal cell proliferation by Wnt pathway activation in a transgenic
zebrafish model. Disease Models & Mechanisms, vol. 6, pp. 802–810.
[122] Lu, R., Wu, S., Zhang, Y. G., et al. (2014). Enteric bacterial protein AvrA promotes
colonic tumorigenesis and activates colonic beta-catenin signaling pathway.
Oncogenesis, vol. 3, e105.
[123] Rhee, K. J., Wu, S., Wu, X., et al. (2009). Induction of persistent colitis by a
human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice.
Infection and Immunity, vol. 77, pp. 1708–1718.
[124] Dabek, M., McCrae, S. I., Stevens, V. J., et al. (2008). Distribution of beta-glucosidase
and beta-glucuronidase activity and of beta-glucuronidase gene gus in human
colonic bacteria. FEMS Microbiology Ecology, vol., 66, pp. 487–495.
[125] DeLuca, J. A., Allred, K. F., Menon, R., et al. (2018). Bisphenol-A alters microbiota
metabolites derived from aromatic amino acids and worsens disease activity during
colitis. Experimental Biology and Medicine, vol. 243, pp. 864–875.
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
[126] Wynendaele, E., Verbeke, F., D’Hondt, M., et al. (2015). Crosstalk between the
microbiome and cancer cells by quorum sensing peptides. Peptides, vol. 64, pp.
40–48.
